ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma

Rationale: Activating transcription factor 4 (ATF4) is a central regulator of the cellular stress response and reduces tumor burden by controlling the expression of target genes implicated in the induction of apoptosis. Evidence shows ATF4 activation is responsible for proteasome inhibitor bortezomib (BTZ)-induced osteosarcoma (OS) cell death. However, it remains unclear how such suppressive function is impaired during prolonged therapeutic interventions. Methods: Stable cells and in vivo xenograft models were generated to reveal the essential role of ATF4 in cell apoptosis and tumor growth. Fluorescence in situ hybridization (FISH) and immunohistochemistry were employed to detect the expression and significance of ATF4 in the specimens from osteosarcoma patients. Biochemical differences between chemoresistant and chemosensitive cancer cells were determined by proliferation, apoptosis, real-time PCR, immunoblotting and immunofluorescence. Promoter activity was analysed using the luciferase reporter assay. Immunoprecipitation was used to explore the interaction of proteins with other proteins or DNAs. Results: ATF4 significantly inhibited OS tumorigenesis, whereas knockdown of ATF4 prevented the antitumor effects of BTZ. Normal osteoblasts are supposed to preferentially express ATF4, but ATF4 silencing was detected in both OS clinical samples and BTZ-resistant sublines (OS/BTZ). We found that ATF4 downregulation was tightly linked to the aberrant expression of RET, primarily due to RET stabilization in OS/BTZ cells. Loss of RET upregulated ATF4 and potentiated the apoptotic response to BTZ. ATF4 recognized the TK domain of RET by recruiting its transactivated E3 ligase Cbl-c to accelerate RET proteasomal turnover, which in turn prevented BTZ resistance. In contrast, the chaperone GRP78 bound to RET and interfered with ATF4/RET interactions, promoted RET stabilization. Intriguingly, ATF4 repressed GRP78 transcription in OS/BTZ cells via the first ERSE, instead of transactivating GRP78 in wild-type OS via classical CRE element, revealing a dual targeting of RET and GRP78 to overcome chemoresistance. Conclusion: The results uncover a crucial role for ATF4 in blocking the progression and resistance response in RET/GRP78-positive human osteosarcoma.

[1]  Chuanfang Wu,et al.  Long noncoding RNA OCC-1 suppresses cell growth through destabilizing HuR protein in colorectal cancer , 2018, Nucleic acids research.

[2]  Elizabeth J. Osterlund,et al.  BCL-2 family proteins: changing partners in the dance towards death , 2017, Cell Death and Differentiation.

[3]  G. Morgan,et al.  Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma , 2017, Leukemia.

[4]  Jun Luo,et al.  GRP78 inhibition enhances ATF4-induced cell death by the deubiquitination and stabilization of CHOP in human osteosarcoma. , 2017, Cancer letters.

[5]  Owen M. McDougal,et al.  Fortilin binds IRE1α and prevents ER stress from signaling apoptotic cell death , 2017, Nature Communications.

[6]  L. Mirabello,et al.  Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy , 2017, Nature Reviews Endocrinology.

[7]  V. Carraro,et al.  Decreased ATF4 expression as a mechanism of acquired resistance to long-term amino acid limitation in cancer cells , 2017, Oncotarget.

[8]  R. Orlowski,et al.  Proteasome inhibitors in cancer therapy , 2017, Nature Reviews Clinical Oncology.

[9]  T. Slaga,et al.  GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy , 2017, Autophagy.

[10]  Michelle D. Williams,et al.  ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer. , 2016, The Journal of clinical endocrinology and metabolism.

[11]  Damian Szklarczyk,et al.  The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..

[12]  I. Plaza-Menacho,et al.  RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements , 2016, Cell reports.

[13]  A. Strasser,et al.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models , 2016, Nature.

[14]  R. Ciampi,et al.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma , 2016, Nature Reviews Endocrinology.

[15]  Randal J. Kaufman,et al.  Protein misfolding in the endoplasmic reticulum as a conduit to human disease , 2016, Nature.

[16]  S. Iida,et al.  Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy , 2015, Blood Cancer Journal.

[17]  Anupama E. Gururaj,et al.  A Novel Dual Kinase Function of the RET Proto-oncogene Negatively Regulates Activating Transcription Factor 4-mediated Apoptosis* , 2015, The Journal of Biological Chemistry.

[18]  Richard Friesner,et al.  Antibody structure determination using a combination of homology modeling, energy‐based refinement, and loop prediction , 2014, Proteins.

[19]  I. Lewis,et al.  Osteosarcoma treatment - where do we stand? A state of the art review. , 2014, Cancer treatment reviews.

[20]  I. Plaza-Menacho,et al.  Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans , 2014, Molecular cell.

[21]  L. Mulligan.  RET revisited: expanding the oncogenic portfolio , 2014, Nature Reviews Cancer.

[22]  Qiang Zhang,et al.  Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. , 2014, Cancer cell.

[23]  C. Tsui,et al.  CD2-associated Protein (CD2AP) Enhances Casitas B Lineage Lymphoma-3/c (Cbl-3/c)-mediated Ret Isoform-specific Ubiquitination and Degradation via Its Amino-terminal Src Homology 3 Domains* , 2014, The Journal of Biological Chemistry.

[24]  J. McClintick,et al.  CHOP induces activating transcription factor 5 (ATF5) to trigger apoptosis in response to perturbations in protein homeostasis , 2013, Molecular biology of the cell.

[25]  R. Kaufman,et al.  ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death , 2013, Nature Cell Biology.

[26]  M. Xing,et al.  Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.

[27]  Xiaogang Wang,et al.  miR-214 targets ATF4 to inhibit bone formation , 2012, Nature Medicine.

[28]  E. Kleinerman,et al.  Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines , 2012, Oncogenesis.

[29]  P. Maher,et al.  Mutation of ATF4 mediates resistance of neuronal cell lines against oxidative stress by inducing xCT expression , 2011, Cell Death and Differentiation.

[30]  H. Ji,et al.  Identification of RET gene fusion by exon array analyses in “pan-negative” lung cancer from never smokers , 2012, Cell Research.

[31]  Martin Dugas,et al.  Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Dowsett,et al.  Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance , 2010, Oncogene.

[33]  R. Flockhart,et al.  Regulation of Endoplasmic Reticulum Stress-induced Cell Death by ATF4 in Neuroectodermal Tumor Cells* , 2009, The Journal of Biological Chemistry.

[34]  M. Santoro,et al.  Targeting the RET Pathway in Thyroid Cancer , 2009, Clinical Cancer Research.

[35]  N. Su,et al.  ATF4-dependent transcription mediates signaling of amino acid limitation , 2009, Trends in Endocrinology & Metabolism.

[36]  A. Harris,et al.  The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. , 2009, Cancer research.

[37]  L. Boise,et al.  Acquisition of a Multidrug Resistant Phenotype with a Proteasome Inhibitor in Multiple Myeloma , 2009, Leukemia.

[38]  B. Pützer,et al.  Transcriptional Repression of the Prosurvival Endoplasmic Reticulum Chaperone GRP78/BIP by E2F1* , 2008, Journal of Biological Chemistry.

[39]  Adrian L Harris,et al.  Activating transcription factor 4. , 2008, The international journal of biochemistry & cell biology.

[40]  Yingang Feng,et al.  Solution structure and mapping of a very weak calcium-binding site of human translationally controlled tumor protein by NMR. , 2007, Archives of biochemistry and biophysics.

[41]  Thomas C. Chen,et al.  The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. , 2007, Cancer research.

[42]  Y. Sasaguri,et al.  Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines , 2007, Oncogene.

[43]  Amy S. Lee.  GRP78 induction in cancer: therapeutic and prognostic implications. , 2007, Cancer research.

[44]  S. Groshen,et al.  GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. , 2006, Cancer research.

[45]  J. Milbrandt,et al.  Glial Cell Line-Derived Neurotrophic Factor-Dependent Recruitment of Ret into Lipid Rafts Enhances Signaling by Partitioning Ret from Proteasome-Dependent Degradation , 2006, The Journal of Neuroscience.

[46]  S. Cole,et al.  Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.

[47]  Amy S. Lee,et al.  Induction of Grp78/BiP by Translational Block , 2003, Journal of Biological Chemistry.

[48]  C. Ibáñez,et al.  Intrinsic susceptibility to misfolding of a hot-spot for Hirschsprung disease mutations in the ectodomain of RET. , 2003, Human molecular genetics.

[49]  Youngchang Kim,et al.  Crystal Structure of the CCAAT Box/Enhancer-binding Protein β Activating Transcription Factor-4 Basic Leucine Zipper Heterodimer in the Absence of DNA* , 2001, The Journal of Biological Chemistry.

[50]  S. Jhiang.  The RET proto-oncogene in human cancers , 2000, Oncogene.